Idioma:

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Osmolovskaya, Yu F ; Zhirov, I V ; Tereshchenko, S N

Terapevtic̆eskii arhiv, 2015-01, Vol.87 (9), p.77-83 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
Autor: Osmolovskaya, Yu F ; Zhirov, I V ; Tereshchenko, S N
Assuntos: aldosterone ; chronic heart failure ; Heart Failure, Systolic - diagnosis ; Heart Failure, Systolic - drug therapy ; Heart Failure, Systolic - physiopathology ; Humans ; mineralocorticoid receptor antagonists ; Mineralocorticoid Receptor Antagonists - pharmacology ; Prognosis ; Randomized Controlled Trials as Topic ; Spironolactone - analogs & derivatives ; Spironolactone - pharmacology ; Treatment Outcome ; Ventricular Function, Left - drug effects
É parte de: Terapevtic̆eskii arhiv, 2015-01, Vol.87 (9), p.77-83
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials. The efficacy of this drug group in patients with chronic HF with preserved left ventricular systolic function and the advent and practical introductions of safer new-generation MCRA remain to be answered.
Editor: Russia (Federation): "Consilium Medicum" Publishing house
Idioma: Russo;Inglês

Links

Voltar para lista de resultados